Lorusso V - Search Results

1

Safety, tolerance, biodistribution, and MR imaging enhancement of the liver with gadobenate dimeglumine: results of clinical pharmacologic and pilot imaging studies in nonpatient and patient volunteers.

Spinazzi A, Lorusso V, Pirovano G, Kirchin M. Spinazzi A, et al. Among authors: lorusso v. Acad Radiol. 1999 May;6(5):282-91. doi: 10.1016/s1076-6332(99)80451-6. Acad Radiol. 1999. PMID: 10228617 Clinical Trial.

2

Pharmacokinetics of gadobenate dimeglumine in children 2 to 5 years of age undergoing MRI of the central nervous system.

Pirovano G, Kirchin MA, Lorusso V, Patel R, Shen N. Pirovano G, et al. Among authors: lorusso v. J Magn Reson Imaging. 2015 Apr;41(4):1096-103. doi: 10.1002/jmri.24653. Epub 2014 May 8. J Magn Reson Imaging. 2015. PMID: 24807269

3

Safety and pharmacokinetics of BR21, a liver-specific CT agent, in healthy volunteers.

Spinazzi A, Ceriati S, Lorusso V, Pianezzola P, Zaccarini P, Fouillet X. Spinazzi A, et al. Among authors: lorusso v. Acad Radiol. 1998 Apr;5 Suppl 1:S20-2; discussion S28-30. doi: 10.1016/s1076-6332(98)80048-2. Acad Radiol. 1998. PMID: 9561035 Clinical Trial. No abstract available.

4

Multihance clinical pharmacology: biodistribution and MR enhancement of the liver.

Spinazzi A, Lorusso V, Pirovano G, Taroni P, Kirchin M, Davies A. Spinazzi A, et al. Among authors: lorusso v. Acad Radiol. 1998 Apr;5 Suppl 1:S86-9; discussion S93-4. doi: 10.1016/s1076-6332(98)80069-x. Acad Radiol. 1998. PMID: 9561052 No abstract available.

5

Safety and pharmacokinetics of a new liposomal liver-specific contrast agent for CT: results of clinical testing in nonpatient volunteers.

Spinazzi A, Ceriati S, Pianezzola P, Lorusso V, Luzzani F, Fouillet X, Alvino S, Rummeny EJ. Spinazzi A, et al. Among authors: lorusso v. Invest Radiol. 2000 Jan;35(1):1-7. doi: 10.1097/00004424-200001000-00001. Invest Radiol. 2000. PMID: 10639031 Clinical Trial.

6

Pharmacokinetics and safety of iomeprol in healthy volunteers and in patients with renal impairment or end-stage renal disease requiring hemodialysis.

Lorusso V, Taroni P, Alvino S, Spinazzi A. Lorusso V, et al. Invest Radiol. 2001 Jun;36(6):309-16. doi: 10.1097/00004424-200106000-00002. Invest Radiol. 2001. PMID: 11410750 Clinical Trial.

7

Compensatory biliary and urinary excretion of gadobenate ion after administration of gadobenate dimeglumine (MultiHance(®)) in cases of impaired hepatic or renal function: a mechanism that may aid in the prevention of nephrogenic systemic fibrosis?

Kirchin MA, Lorusso V, Pirovano G. Kirchin MA, et al. Among authors: lorusso v. Br J Radiol. 2015 Apr;88(1048):20140526. doi: 10.1259/bjr.20140526. Epub 2015 Feb 4. Br J Radiol. 2015. PMID: 25651409 Free PMC article. Clinical Trial.

8

Pharmacokinetics and safety of gadobenate dimeglumine (multihance) in subjects with impaired liver function.

Davies BE, Kirchin MA, Bensel K, Lorusso V, Davies A, Parker JR, Lafrance ND. Davies BE, et al. Among authors: lorusso v. Invest Radiol. 2002 May;37(5):299-308. doi: 10.1097/00004424-200205000-00008. Invest Radiol. 2002. PMID: 11979156 Clinical Trial.

9

Hepatic transport of the magnetic resonance imaging contrast agent gadobenate dimeglumine in the rat.

de Haën C, Lorusso V, Luzzani F, Tirone P. de Haën C, et al. Among authors: lorusso v. Acad Radiol. 1995 Mar;2(3):232-8. doi: 10.1016/s1076-6332(05)80171-0. Acad Radiol. 1995. PMID: 9419554

10

Hepatic transport of gadobenate dimeglumine in TR-rats.

de Haën C, Lorusso V, Tirone P. de Haën C, et al. Among authors: lorusso v. Acad Radiol. 1996 Aug;3 Suppl 2:S452-4. doi: 10.1016/s1076-6332(96)80614-3. Acad Radiol. 1996. PMID: 8796627 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

441 results

Search Page

Filters